How it works, simply
It mimics somatostatin, a signal that slows the release of certain hormones.
What the evidence tells us
Uses and schedules differ by formulation and condition; this is not a general hormone-balancing product.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Gallbladder problems and changes in blood glucose can occur.
- Heart-rate and thyroid effects are also described in the product label.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Binds somatostatin receptors and suppresses selected endocrine secretions.
Sponsor or developer: Multiple manufacturers
Studied or labeled topics: Acromegaly, Carcinoid syndrome, VIPoma
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: SANDOSTATIN prescribing information ↗ · Regulator · Jul 24, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.